Cancer Immunotherapy in Solid Organ Transplanted Patients

Yıl 2020, , 87 - 96, 26.08.2020

Ali Abdi Fatma Betül Öktelik Mehtap Doğruel Biçer Ali Osman Gürol

https://doi.org/10.26650/experimed.2020.0036

Öz

Solid-organ transplantation, which began as an experimental procedure in the 20th century, has become an established, definitive, and practicable treatment option for patients with organ dysfunction. However, since the pioneering days of solid organ transplantation, it has been recognized that transplant recipients have an elevated risk of developing cancer. When compared with healthy individuals, lung, liver, heart, and kidney transplant recipients are at a higher risk for various cancers. Both chronic immunosuppression and environmental factors are implicated in cancer development in the transplant recipients. A history of malignancy and genetic predisposition are additional risk factors. Post-transplant malignancies are thought to develop by three mechanisms: de novo development, donor-related transmission, and recurrence of a recipient’s pre-transplant malignancy. Other known risk factors are environmental exposure, genetic predisposition, and infection with oncogenic viruses. It is worth noting that many of these risk factors are linked with the use of immunosuppression drugs. These agents play a huge role in the development of cancer through the loss of the immunosurveillance process and the requirement of patients to receive lifelong immunosuppressive therapy to prevent rejection of the donor organ. Even though the field of anticancer therapy is continually developing, there is limited data on the use of anticancer drugs in transplant recipients. Hence, this review attempts to explain the role of immunosuppression in cancer development and the cancer immunotherapy strategies to be adopted while caring for transplant recipients.

Anahtar Kelimeler

Solid-organ transplantation, cancer, immunosuppression, immunotherapy

Solid-Organ Transplantasyonu Olan Hastalarda Kanser İmmünoterapisi

Öz

Solid organ transplantasyonu 20. yüzyılda deneysel bir yaklaşımdan ortaya çıkmış ve organ fonksiyon bozukluğu olan hastalar için yerleşik ve pratik bir kesin tedavi seçeneği haline gelmiştir. Terminal olarak kabul edilen veya bir hastanın yaşam kalitesinde önemli bir bozulma ile ilişkili hastalıklar için hayat kurtarıcı tedaviler sunmaktadır. Solid organ transplantasyonunun ilk günlerinden beri, solid transplant alıcılarının kanser geliştirme riskinin yüksek olduğu kabul edilmektedir. Toplumda sağlıklı bireylere göre karşılaştırıldığında akciğer, karaciğer, kalp veya böbrek nakli alıcıları çeşitli kanserler için daha fazla risk taşımaktadır. Kronik immünsüpresyon ve çevresel faktörler, alıcılarda kanser gelişiminde rol oynamaktadır. Ayrıca daha önce malignite öyküsü olması ve genetik yatkınlık önemli riskler arasındadır. Transplantasyon sonrası malignitelerin üç mekanizma ile geliştiği düşünülmektedir: de novo gelişim, donör ile ilgili bulaşma ve alıcının transplantasyon öncesi malignitesinin tekrarlaması. Bilinen risk faktörleri genetik, çevresel maruziyetler, onkojenik virüslerle enfeksiyonlardır. Ancak bu risklerin çoğu immünsüpresif ajanların rolüne odaklanmıştır. Bu ajanlar, immün gözetim sürecinin kaybını ve donör organın reddini önlemeyi hedefler. Hastaların ömür boyu immün sistemini baskılayıcı tedavi alma gereksinimi kanserin gelişiminde büyük rol oynamaktadır. Ayrıca, antikanser ajan alanı, transplantasyon alıcılarındaki kullanımla ilgili verilerin sınırlı olmasıyla birlikte, sürekli olarak genişlemekte ve gelişmektedir. Bu nedenle, bu derlemenin amacı, kanser gelişiminde immünsüpresyonun rolünü açıklamak ve transplant alıcılarının bakımı için kanser immünoterapi stratejilerini gözden geçirmektir.

Anahtar Kelimeler

Solid organ transplantasyonu, kanser, immünsüpresyon, immünoterapi

Kaynakça

• 1. Chapman JR, Webster AC, Wong G. Cancer in the transplant recipient. Cold Spring Harbor Perspectives in Medicine 2013; 3(7): a015677. [CrossRef]
• 2. Campistol JM, Cuervas-Mons V, Manito N, Almenar L, Arias M, Casafont F, et al. New concepts and best practices for management of pre-and post-transplantation cancer. Transplantation Reviews 2012; 26(4): 261-79. [CrossRef]
• 3. Katabathina VS, Menias CO, Tammisetti VS, Lubner MG, Kielar A, Shaaban A, et al. Malignancy after Solid Organ Transplantation: Comprehensive Imaging Review. Radiographics: a review publication of the Radiological Society of North America, Inc 2016; 36(5): 1390-407. [CrossRef]
• 4. Gurol AO, Okten-Kursun A, Kasapoglu P, Suzergoz F, Kucuksezer UC, Cevik A, et al. The synergistic effect of omega3 and Vit D3 on glycemia and TNF-alpha in islet transplantation. Cell Mol Biol (Noisy-le-grand) 2016; 62(1): 90-8.
• 5. Khatri R, Hussmann B, Rawat D, Gurol AO, Linn T. Intraportal Transplantation of Pancreatic Islets in Mouse Model. J Vis Exp 2018(135). [CrossRef]
• 6. Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients. Drugs 2007; 67(8): 1167-98. [CrossRef]
• 7. Acuna SA, Huang JW, Scott AL, Micic S, Daly C, Brezden-Masley C, et al. Cancer Screening Recommendations for Solid Organ Transplant Recipients: A Systematic Review of Clinical Practice Guidelines. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2017; 17(1): 103-14. [CrossRef]
• 8. Rama I, Grinyó JM. Malignancy after renal transplantation: the role of immunosuppression. Nature Reviews Nephrology 2010; 6(9): 511. [CrossRef]
• 9. Rezaei N, Aalaei-Andabili SH, Amini N, Delavari F, Keshavarz-Fathi M, Kaufman HL. Introduction on cancer immunology and immunotherapy. Cancer immunology: Springer; 2020. p. 1-9. [CrossRef]
• 10. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2010; 28(19): 3167-75. [CrossRef]
• 11. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. New England Journal of Medicine 2015; 372(4): 320-30. [CrossRef]
• 12. Kittai AS, Oldham H, Cetnar J, Taylor M. Immune checkpoint inhibitors in organ transplant patients. Journal of Immunotherapy 2017; 40(7): 277-81. [CrossRef]
• 13. Pilch NA, Meadows HB, Alloway RR. Monoclonal Antibodies in Solid Organ Transplantation. In: Crommelin DJA, Sindelar RD, Meibohm B, editors. Pharmaceutical Biotechnology: Fundamentals and Applications. New York, NY: Springer New York; 2013. p. 37591.
• 14. Morris D, Thompson B, Coffey M. Combination of transplantation and oncolytic virus treatment. Google Patents; 2005.
• 15. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nature Reviews Cancer 2004; 4(10): 757-68. [CrossRef]
• 16. Dharnidharka VR, Webster AC, Martinez OM, Preiksaitis JK, Leblond V, Choquet S. Post-transplant lymphoproliferative disorders. Nature Reviews Disease Primer 2016; 2(1): 1-20. [CrossRef]
• 17. Kim M, Rahman MM, Cogle CR, McFadden G. Prevention of EBV lymphoma development by oncolytic myxoma virus in a murine xenograft model of post-transplant lymphoproliferative disease. Biochemical and Biophysical Research Communications 2015; 462(4): 283-7. [CrossRef]
• 18. Alkayyal AA, Mahmoud AB, Auer RC. Interleukin-12-expressing oncolytic virus: A promising strategy for cancer immunotherapy. Journal of Taibah University Medical Sciences 2016; 11(3): 187-93. [CrossRef]
• 19. Moesta AK, Cooke K, Piasecki J, Mitchell P, Rottman JB, Fitzgerald K, et al. Local Delivery of OncoVEXmGM-CSF Generates Systemic Antitumor Immune Responses Enhanced by Cytotoxic T-Lymphocyte-Associated Protein Blockade. Clinical Cancer Research 2017; 23(20): 6190-202. [CrossRef]
• 20. Martikainen M, Essand M. Virus-based immunotherapy of glioblastoma. Cancers 2019; 11(2): 186. [CrossRef]
• 21. Yan Y, Xu H, Wang J, Wu X, Wen W, Liang Y, et al. Inhibition of breast cancer cells by targeting E2F-1 gene and expressing IL15 oncolytic adenovirus. Bioscience Reports 2019; 39(7). [CrossRef]
• 22. Patel DM, Foreman PM, Nabors LB, Riley KO, Gillespie GY, Markert JM. Design of a phase I clinical trial to evaluate M032, a genetically engineered HSV-1 expressing IL-12, in patients with recurrent/ progressive glioblastoma multiforme, anaplastic astrocytoma, or gliosarcoma. Human Gene Therapy Clinical Development 2016; 27(2): 69-78. [CrossRef]
• 23. Post DE, Sandberg EM, Kyle MM, Devi NS, Brat DJ, Xu Z, et al. Targeted Cancer Gene Therapy Using a Hypoxia Inducible Factor-Dependent Oncolytic Adenovirus Armed with Interleukin-4. Cancer Research 2007; 67(14): 6872-81. [CrossRef]
• 24. Oh E, Hong J, Kwon O-J, Yun C-O. A hypoxia-and telomerase-responsive oncolytic adenovirus expressing secretable trimeric TRAIL triggers tumour-specific apoptosis and promotes viral dispersion in TRAIL-resistant glioblastoma. Scientific Reports 2018; 8(1): 1-13. [CrossRef]
• 25. Zhang Q, Liu F. Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas. Cell Death & Disease 2020; 11(6): 1-11. [CrossRef]
• 26. Lilly CL, Villa NY, Lemos de Matos A, Ali HM, Dhillon J-KS, Hofland T, et al. Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor. Molecular Therapy - Oncolytics 2017; 4: 31-40. [CrossRef]
• 27. Katabathina V, Menias CO, Pickhardt P, Lubner M, Prasad SR. Complications of immunosuppressive therapy in solid organ transplantation. Radiologic Clinics 2016; 54(2): 303-19. [CrossRef]
• 28. Safinia N, Grageda N, Scottà C, Thirkell S, Fry LJ, Vaikunthanathan T, et al. Cell Therapy in Organ Transplantation: Our Experience on the Clinical Translation of Regulatory T Cells. Front Immunol 2018; 9: 354. [CrossRef]
• 29. Tang Q, Lee K. Regulatory T-cell therapy for transplantation: how many cells do we need? Current Opinion in Organ Transplantation 2012; 17(4): 349-54. [CrossRef]
• 30. Todo S, Yamashita K, Goto R, Zaitsu M, Nagatsu A, Oura T, et al. A pilot study of operational tolerance with a regulatory T‐cell‐based cell therapy in living donor liver transplantation. Hepatology 2016; 64(2): 632-43. [CrossRef]
• 31. McCurry KR, Colvin BL, Zahorchak AF, Thomson AW. Regulatory dendritic cell therapy in organ transplantation. Transplant International. 2006; 19(7): 525-38. [CrossRef]
• 32. Noyan F, Zimmermann K, Hardtke‐Wolenski M, Knoefel A, Schulde E, Geffers R, et al. Prevention of allograft rejection by use of regulatory T cells with an MHC‐specific chimeric antigen receptor. American Journal of Transplantation 2017; 17(4): 917-30. [CrossRef]
• 33. Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood, The Journal of the American Society of Hematology 2011; 117(14): 3921-8. [CrossRef]
• 34. Boardman D, Maher J, Lechler R, Smyth L, Lombardi G. Antigen-specificity using chimeric antigen receptors: the future of regulatory T-cell therapy? Biochemical Society Transactions 2016; 44(2): 342-8. [CrossRef]
• 35. Zhang Q, Lu W, Liang C-L, Chen Y, Liu H, Qiu F, et al. Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance. Front Immunol 2018; 9: 2359. [CrossRef]
• 36. Burt C, Cryer C, Fuggle S, Little AM, Dyer P. HLA‐A,‐B,‐DR allele group frequencies in 7007 kidney transplant list patients in 27 UK centres. International Journal of Immunogenetics 2013; 40(3): 209-15. [CrossRef]
• 37. Magnani G, Falchetti E, Pollini G, Reggiani LB, Grigioni F, Coccolo F, et al. Safety and efficacy of two types of influenza vaccination in heart transplant recipients: a prospective randomised controlled study. The Journal of Heart and Lung Transplantation 2005; 24(5): 588-92. [CrossRef]
• 38. Khan S, Erlichman J, Rand EB. Live virus immunization after orthotopic liver transplantation. Pediatric Transplantation 2006; 10(1): 78-82. [CrossRef]
• 39. Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. The Lancet 2007; 370(9581): 29-38. [CrossRef]
• 40. Control CfD, Prevention. HIV/AIDS Surveillance Report: Cases of HIV infection and AIDS in the United States, 2004. HIV/AIDS Surveillance Report 2004; 14.
• 41. Markowitz L. Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices (ACIP): Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56: 1-24. [CrossRef]
• 42. Gabriel R, Selwyn S, Brown D, Crossland J, Loughridge LW, Morgan N, et al. Virus infections and acute renal transplant rejection. Nephron 1976; 16(4): 282-6. [CrossRef]
• 43. Fenton K, Lowndes C. Recent trends in the epidemiology of sexually transmitted infections in the European Union. Sexually Transmitted Infections 2004; 80(4): 255-63. [CrossRef]
• 44. Broyer M, Tete MJ, Guest G, Gagnadoux MF, Rouzioux C. Varicella and zoster in children after kidney transplantation: long-term results of vaccination. Pediatrics 1997; 99(1): 35-9. [CrossRef]
• 45. Hanaway MJ, Woodle ES, Mulgaonkar S, Peddi VR, Kaufman DB, First MR, et al. Alemtuzumab induction in renal transplantation. New England Journal of Medicine 2011; 364(20): 1909-19. [CrossRef]
• 46. McCurry KR, Iacono A, Zeevi A, Yousem S, Girnita A, Husain S, et al. Early outcomes in human lung transplantation with Thymoglobulin or Campath-1H for recipient pretreatment followed by posttransplant tacrolimus near-monotherapy. The Journal of Thoracic and Cardiovascular Surger 2005; 130(2): 528-37. [CrossRef]
• 47. Rosenberg PB, Vriesendorp AE, Drazner MH, Dries DL, Kaiser PA, Hynan LS, et al. Induction therapy with basiliximab allows delayed initiation of cyclosporine and preserves renal function after cardiac transplantation. The Journal of Heart and Lung Transplantation 2005; 24(9): 1327-31. [CrossRef]
• 48. Ferguson R, Grinyo J, Vincenti F, Kaufman D, Woodle E, Marder B, et al. Immunosuppression with belatacept‐based, corticosteroidavoiding regimens in de novo kidney transplant recipients. American Journal of Transplantation 2011; 11(1): 66-76. [CrossRef]
• 49. McKeage K. Eculizumab. Drugs 2011; 71(17): 2327-45. [CrossRef]
• 50. MacDonald KG, Hoeppli RE, Huang Q, Gillies J, Luciani DS, Orban PC, et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. The Journal of clinical investigation 2016; 126(4): 1413-24. [CrossRef]
• 51. Boardman DA, Philippeos C, Fruhwirth GO, Ibrahim MA, Hannen RF, Cooper D, et al. Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection. American Journal of Transplantation 2017; 17(4): 931-43. [CrossRef]